Stockwinners Market Radar for April 04, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment bought 2.61M shares of Butterfly Network today

19:13 EDT Dominari Holdings CEO buys $103K in common stock - In a regulatory filing, Dominari Holdings disclosed that its CEO Anthony Hayes bought 30K shares of common stock on April 4th in a total transaction size of $103.1K. Shares of Dominari Holdings are up 4.8% afterhours at $3.53.

19:01 EDT Hycroft Mining granted 180-day extension by Nasdaq to regain compliance - Hycroft Mining announced it has received an extension of 180 calendar days or until October 2, 2023, to regain compliance with Nasdaq's minimum bid price requirement. Nasdaq's determination is based on the company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

17:45 EDT GAP Airports reports March 2023 passenger traffic up 15.8% y/y - GAP Airports announced preliminary terminal passenger traffic figures for the month of March 2023, compared with the same period of 2022. For March 2023, the total number of terminal passengers at GAP's 12 Mexican airports increased by 14.2%, compared to the same period in 2022. Guadalajara, Los Cabos, Puerto Vallarta, and Tijuana presented an increase in passenger traffic of 19.1%, 15.4%, 14.6%, and 8.0% respectively, compared to March 2022. On the other hand, Montego Bay increased by 27.4% and Kingston by 38.1%, compared to 2022.

17:12 EDT Gran Tierra: During Q1 total average production 31,700 BOPD - Commenting on the Company's ongoing successful drilling campaign and share and bond buyback programs, Gary Guidry, President and Chief Executive Officer of Gran Tierra, stated: "We are very pleased with the results so far from our 2023 development drilling campaign, which have demonstrated the quality of our assets and our ability to execute on our strategy. We plan to continue the development program until the end of second quarter 2023, with our high-impact exploration drilling campaign scheduled to commence early in third quarter 2023. We are also pleased with the resumption of both our share and bond buyback programs, which reflect our commitment to returning value to our shareholders and strengthening our balance sheet. "During first quarter 2023,Gran Tierra's total average production was approximately 31,700 BOPD. Gran Tierra's total current average production1 for second quarter 2023 to date is approximately 33,700 BOPD, which is at the high end of the Company's 2023 previously disclosed average annual production guidance. During second quarter 2023 to date, Acordionero's current average production1 is approximately 20,000 BOPD, which is the first time this level of production has been reached since second quarter 2019 and is a result of the Company's ongoing successful development drilling and asset management efforts through waterflooding to enhance oil recovery.

17:07 EDT NovaGold sees FY23 capital spending roughly $31M - NOVAGOLD's primary goals in 2023 are to continue to advance the Donlin Gold project toward a construction decision; maintaining support for Donlin Gold among the project's stakeholders; promoting a strong safety, sustainability, and environmental culture; maintaining a favorable reputation of NOVAGOLD; and preserving a healthy balance sheet. Our operations primarily relate to the delivery of project milestones, including the achievement of various technical, environmental, sustainable development, economic and legal objectives, obtaining necessary permits, completion of pre-feasibility and feasibility studies, preparation of engineering designs and the financing to fund these objectives.

17:00 EDT Barings BDC CFO Jonathan Landsberg to step down - On March 30, 20223, Jonathan Landsberg "notified Barings BDC that he will step down as the Company's Chief Financial Officer, effective as of the close of business on April 4, 2023, to pursue other business opportunities. Mr. Landsberg's resignation is not a result of any disagreement with the Company on any matter relating to its operations, policies, or practices, or to any issues regarding its accounting policies or practices. On April 3, 2023, the Company's Board of Directors appointed Elizabeth Murray as Chief Financial Officer of the Company, effective as of the close of business on April 4, 2023. Ms. Murray will continue to serve as the Company's Chief Operating Officer and Chief Accounting Officer."

16:53 EDT Johnson & Johnson spikes over 3% after nearly $9B settlement on talc claims - Shares of Johnson & Johnson are up approximately $5 per share or over 3% in after-hours trading on Tuesday to $164 per share after announcing a nearly $9B settlement over claims that its talcum powder causes cancer.

16:35 EDT Kura Sushi jumps 6.5% to $71.69 per share after Q2 earnings beat and guidance

16:33 EDT Walmart sees roughly 65% of stores serviced by automation by end of FY26 - By the end of Fiscal Year 2026, Walmart believes roughly 65% of stores will be serviced by automation, approximately 55% of the fulfillment center volume will move through automated facilities, and unit cost averages could improve by approximately 20%. As the changes are implemented across the business, one of the outcomes is roles that require less physical labor but have a higher rate of pay. Over time, the company anticipates increased throughput per person, due to the automation while maintaining or even increasing its number of associates as new roles are created. "It all starts with our associates," McMillon said. "We are a people-led, tech-powered omnichannel retailer. As it relates to being people-led, it's about purpose, values, culture, opportunity and belonging. We serve our associates by creating opportunities. Opportunities that turn jobs into careers. We help bring dignity to work by enabling them to see how they're serving others, as part of a team, and helping them achieve their potential. And as we serve them, they serve our customers and members well...they make the difference."

16:29 EDT Servotronics announces details of strategic vision, operating plan - Servotronics announced details of its strategic vision to improve operational effectiveness and help drive sustainable growth and long-term shareholder value. "Within the last twelve months the Company made considerable progress in revitalizing its leadership and culture. Steps included: Named William F. Farrell, Jr. as Chief Executive Officer to lead a transformation and revitalization of the culture and business results. Refreshed the Board of Directors with three new independent directors and a non-executive Chairman to enhance overall governance and bring fresh perspectives to leadership...Strengthened the corporate leadership team, including the addition of a new Director of Human Resources and two executives to lead its Advanced Technology Group and Consumer Products Group segments. Announced the pursuit of strategic alternatives for CPG to align long-term strategic focus on Servotronics' core aerospace business. "Our team has made tremendous progress over the past year to revitalize our culture and define a long-term strategic vision for the business," said Chief Executive Officer William F. Farrell, Jr. "Our efforts to create additional value for all stakeholders began with the refresh of our corporate culture to drive integrity and accountability. In addition, we have added leadership team members that exemplify this change and bring capabilities to improve the performance of our Company. This transformation will enhance our operational effectiveness, create profitable growth, and result in long-term value for our employees, customers, and shareholders."...In support of the implementation of the Company's new long-term strategic vision, the Leadership Team has developed a 5-year operating plan to drive profitable growth. By executing the strategic plan, targeted improvements in financial results include: Mid-single-digit revenue growth which is in line with, or slightly higher than, projected industry growth. A return to pre-pandemic gross margins, representing meaningful improvement in profitability over the 5-year time horizon. Chief Executive Officer William F. Farrell, Jr. concluded, "Our refreshed Board of Directors and new Leadership Team are guiding the Company through a culture change, and driving our updated strategy. We are respecting Servotronics's historical strengths and are accelerating to the future on our newly developed strategic path. This transformation will create improved financial performance and value for all of our stakeholders."

16:26 EDT Compass Minerals to eliminate 16% of corporate workforce in cost cutting plan - In a regulatory filing, Compass Minerals disclosed that on April 4, the company "took initial steps to align the company's cost structure to its current business needs." Compass Minerals said: "These steps will assist the company's cost control efforts as it focuses on maximizing the profitability of its core Salt and Plant Nutrition businesses while pursuing growth into the adjacent, high-value markets of lithium and next-generation fire retardants. Specifically, the company eliminated 48.5 full-time employee positions, representing approximately 16% of its corporate workforce. All employees whose positions were eliminated have been offered severance packages, including outplacement services. The company expects to incur a charge in connection with these terminations of approximately $3.3M in fiscal 2023, approximately $2.8 M of which will be recognized in the quarter ended March 31, 2023. For full-year fiscal 2024, the company believes these actions, along with the elimination of certain consulting and other overhead costs after fiscal 2023, will benefit its operating expenses and adjusted EBITDA in the range of $17M-$18M per year. This reduction in operating costs is the result of the company's efforts to right-size its cost structure. In the coming months, the company intends to focus on thoroughly evaluating costs at its production and packaging sites to identify potential, additional cost-reduction opportunities."

16:13 EDT NGM Biopharmaceuticals sees cash sufficient to fund operations into Q2 of 2025 - NGM Biopharmaceuticals announced that, in connection with the implementation of a restructuring, the company believes that its existing cash, cash equivalents and short-term marketable securities will be sufficient to fund its operations into the second quarter of 2025. "The company has based this estimate on plans and assumptions that may prove to be insufficient or inaccurate (for example, with respect to anticipated costs, timing or success of certain activities), and the company could utilize its available financial resources sooner than it currently expects," NGM stated in a regulatory filing.

16:12 EDT NGM Biopharmaceuticals reports Chief Scientific Officer resigned - In a regulatory filing, NGM Biopharmaceuticals disclosed that on April 3 Jin-Long Chen, Ph.D. resigned as Chief Scientific Officer of the company, and as a member of the board, in each case effective as of April 4. "The Board has accepted Dr. Chen's resignation and is grateful for his many contributions to the company that he founded in 2008," the company stated.

16:11 EDT InterPrivate III Financial deadline for initial business combination extended - InterPrivate III Financial Partners I announced that its board of directors has decided to extend the date by which the Company must consummate an initial business combination from April 9, for an additional month, to May 9, 2023, the second of three potential one-month extensions of the Deadline Date available to the Company. The Company's Amended and Restated Certificate of Incorporation provides the Company the right to extend the Deadline Date up to three times for an additional one month each time from March 9 to up to June 9. As previously disclosed, in December 2022, the Board had implemented a first Extension and had extended the initial Deadline Date to April 9 . On March 29 pursuant to the Charter, the Board determined to implement a second Extension to allow additional time for the Company to complete its initial business combination. In connection with the second Extension, the Company deposited $120,100.56 for the second month of the Extension. On April 4 the Company deposited such contribution into the Company's trust account.

16:07 EDT Thorne HealthTech shares findings of collaborative trial with Mayo Clinic - Thorne HealthTech shared significant positive findings as a result of a collaborative trial with Mayo Clinic and HealthTech Connex, "The effects of a dietary supplement on brain function and structure in Junior A ice hockey players: a prospective randomized trial." The results are now available on Medrxiv. The double-blinded, placebo-controlled trial measured the brain function of 30 ice hockey players over the course of their season. The trial was led by Mayo Clinic's Dr. Michael Stuart who was the Principal Investigator. The purpose of the study was to determine whether a nutritional supplement - designed to address specific mechanisms of action associated with head impact - could favorably affect those functions over the course of a hockey season. Participants went through baseline brain function testing at the beginning of the season, then consumed either Thorne's SynaQuell or a placebo daily for the duration of their season. At the end of the study, the same brain function tests were repeated and compared. The full study and results are expected to be available later this year.

16:05 EDT Marchex names Troy Hartless as Chief Revenue Officer - Marchex "announced that Troy Hartless has joined the company as Chief Revenue Officer. Hartless has extensive experience as an executive officer for both private and publicly traded technology companies, and will lead Marchex's sales, marketing, business development, solutions consulting and customer success organizations. Most recently, Hartless was COO of Govplace, a cloud, cybersecurity, and perimeter security solutions company which he led through COVID while returning the business to profitability."

16:04 EDT Celyad receives noncompliance letter from Nasdaq - Celyad received a letter on March 31 from Nasdaq informing the company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450 for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10M.

16:01 EDT Celyad discloses Nasdaq listing notice - Celyad Oncology received a letter on March 31, 2023 from The Nasdaq Stock Market informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million. Based upon the reported stockholders' equity of approximately $4.6 million in the Company's Form 20-F for the period ended December 31, 2022, the Company did not meet the Stockholders' Equity Requirement. The Company has a period of 45 calendar days from the date of the Letter, or until May 15, 2023, to submit a plan to regain compliance with the Stockholders' Equity Requirement. If such a plan is submitted and accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Letter for the Company to regain compliance.

15:05 EDT InflaRx up 47% after receiving EUA for Gohibic use in COVID-19 treatment - Share of InflaRx are up 97c, or 47%, to $3.02 in afternoon trading.

14:57 EDT InflaRx announces Gohibic receives FDA Emergency Use Authorization - InflaRx N.V. announced that Gohibic, a first-in-class monoclonal anti-human complement factor C5a antibody, has been granted an Emergency Use Authorization by the U.S. Food and Drug Administration for the treatment of coronavirus disease 19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, or ECMO. "InflaRx continues discussions with FDA related to submission of a BLA for full approval of Gohibic in this COVID-19 indication. InflaRx has also completed encouraging meetings with the rapporteur and co-rapporteur teams of the European Committee for Medicinal Products for Human Use, CHMP, related to a planned Marketing Authorization Application with the European Medicines Agency, or EMA. In addition, InflaRx is continuing to develop vilobelimab in other indications, including pyoderma gangrenosum, for which the Company is currently initiating a Phase III trial," the company stated.

14:01 EDT General Dynamics unit awarded $1.7B U.S. Army contract - General Dynamics Information Technology, or GDIT, a business unit of General Dynamics, announced that it was awarded the Flight School Training Support Services contract to support the U.S. Army Aviation Center of Excellence. Awarded in March, the $1.7B contract, managed by the U.S. Army Program Executive Office for Simulation, Training and Instrumentation, has a five-year base period and seven option years.

13:35 EDT UK watchdog fines TikTok GBP 12.7M for failing to protect children's data - The ICO, UK's independent body set up to uphold information rights, said in an earlier statement: "The Information Commissioner's Office, ICO, has issued a GBP 12,700,000 fine to TikTok Information Technologies UK Limited and TikTok for a number of breaches of data protection law, including failing to use children's personal data lawfully. The ICO estimates that TikTok allowed up to 1.4M UK children under 13 to use its platform in 2020, despite its own rules not allowing children that age to create an account. UK data protection law says that organisations that use personal data when offering information society services to children under 13 must have consent from their parents or carers.TikTok failed to do that, even though it ought to have been aware that under 13s were using its platform. TikTok also failed to carry out adequate checks to identify and remove underage children from its platform.The ICO investigation found that a concern was raised internally with some senior employees about children under 13 using the platform and not being removed. In the ICO's view TikTok did not respond adequately. John Edwards..."There are laws in place to make sure our children are as safe in the digital world as they are in the physical world. TikTok did not abide by those laws." Publicly traded companies in the social space include Meta Platforms (META), Pinterest (PINS), Snap (SNAP), Alphabet (GOOG, GOOGL) and Twitter (TWTR). Reference Link

13:01 EDT Quad wins multimillion dollar contract to print Reader's Digest - Quad announced that it is now the sole printer of the U.S. edition of Reader's Digest. The new, multi-million-dollar contract spans the next three years, it said in a statement. "We're proud to be working with such an esteemed brand and to have been able to move all of their production from their previous printer to our Lomira, Wis., facility in just one month. Even as Quad expands into growing areas of the marketing experience, printing continues to be a legacy part of our business. This frictionless transition is indicative of how Quad does business everywhere," said Quad's Executive Vice President of Manufacturing, Daren Robarge.

12:26 EDT Multi Ways Holdings Ltd trading halted, volatility trading pause

12:02 EDT TPG, Thomson Reuters deal values Elite at about $500M

12:00 EDT Virgin Galactic falls -13.5% - Virgin Galactic is down -13.5%, or -53c to $3.35.

12:00 EDT C3.ai falls -23.1% - C3.ai is down -23.1%, or -$7.81 to $26.06.

12:00 EDT IonQ rises 11.5% - IonQ is up 11.5%, or 71c to $6.86.

11:23 EDT Kontrol Technologies receives BioCloud U.S. patent - Kontrol Technologies receives its first Kontrol BioCloud technology patent. The Company continues to grow its patent portfolio for Kontrol BioCloud and Kontrol BioWater technologies. The U.S. patent 11,619,571 COLLECTION CHAMBER FOR AN AIR SAMPLING SYSTEM relates to an Air Sampling System having, among other features, an air intake unit defining an inlet and an air inflow channel; a fan configured to cause air in a sampling environment to flow into the air inflow channel via the inlet; a cooling unit for cooling air in the air inflow channel; a collection chamber for collecting liquid water condensed from air in the air inflow channel, the collection chamber being removably coupled to the air intake unit and including an active target substrate having a surface that is coated with bioreceptors; a flow column that is centrally disposed inside the collection chamber, the flow column being fluidly connected to the air inflow channel and defining a plurality of apertures through which fluid flows into the collection chamber; and an optical detection unit including a light source, the optical detection unit being configured to illuminate the active target substrate with the light source, wherein the collection chamber includes: a plurality of glass beads disposed in an annular space between the flow column and an inner wall of the collection chamber, wherein surfaces of the plurality of glass beads are exposed to liquid that collects in the collection chamber; and a permeable stopper that supports the plurality of glass beads above and in spaced relation to a bottom wall of the collection chamber, wherein the active target substrate is disposed in a reaction compartment defined by the stopper and the bottom wall of the collection chamber.

10:39 EDT GM sees coming in at higher end of 30%-50% of savings program realized this year

10:18 EDT Linde enters agreement with Exxon Mobil for carbon dioxide off-take - Linde (LIN) announced that it has signed a long-term agreement with ExxonMobil (XOM) for the off-take of carbon dioxide associated with Linde's new clean hydrogen production in Beaumont, Texas. Under the terms of the agreement, ExxonMobil will transport and permanently store up to 2.2 million metric tons of carbon dioxide each year from Linde's hydrogen production facility, equivalent to the emissions from nearly half a million cars per year.

10:15 EDT Rackspace Technology, Braze enter multi-year agreement - Rackspace Technology (RXT) announced that Braze (BRZE) has expanded its relationship with Rackspace Technology with a multi-year agreement that will support growth and innovation for the company.

10:00 EDT C3.ai falls -9.6% - C3.ai is down -9.6%, or -$3.26 to $30.61.

10:00 EDT Encompass Health rises 10.6% - Encompass Health is up 10.6%, or $5.76 to $59.86.

10:00 EDT Signa Sports rises 16.3% - Signa Sports is up 16.3%, or 54c to $3.86.

09:47 EDT Acuity Brands falls -7.0% - Acuity Brands is down -7.0%, or -$12.77 to $170.56.

09:47 EDT AMC Entertainment falls -16.4% - AMC Entertainment is down -16.4%, or -84c to $4.27.

09:47 EDT ZIM Integrated rises 9.5% - ZIM Integrated is up 9.5%, or $1.62 to $18.69.

09:38 EDT AMC Entertainment trading resumes

09:31 EDT Duolingo exec sells $701K in common stock - In a regulatory filing, Duolingo disclosed that its Chief Business Officer Robert Meese sold 5K shares of common stock on March 31st in a total transaction size of $701K.

09:28 EDT Bare Knuckle Fighting Championship joins Rumble sports lineup - Rumble announced the addition of Bare Knuckle Fighting Championship to its growing roster of live sports leagues. Along with the popular combat sport Power Slap, Rumble continues to ramp up its sports lineup with the recent addition of BKFC. BKFC will kick off its Rumble distribution with a press conference for BFKC-41 at the Palm Casino Resort in Las Vegas, Nevada, on Tuesday, April 4th at 12 p.m. PT. Hosted by David Feldman, President and Founder of BKFC, the press conference will feature MMA legends including Chael Sonnen, 'Platinum' Mike Perry, Luke Rockhold, Chad Mendes, Eddie Alvarez, and others. BKFC-41 will be broadcast worldwide on pay-per-view Saturday, April 29th from the 1STBANK Center in Broomfield, Colorado.

09:26 EDT Ford's Kansas City Assembly Plant to add third crew in April - The company plans to increase production for Ford Pro of the Transit and E-Transit vans.

09:22 EDT Ford reports Q1 total sales up 10.7% to 456,972 vehicles

09:19 EDT Alkaline Water announces 15-for-1 reverse stock split - Alkaline Water announced that its board of directors approved a 15-for-1 reverse stock split of the company's authorized and issued and outstanding shares of common stock, which will be effective under Nevada law on April 5. The company's common stock will continue to trade on Nasdaq and will be open for trading on a split-adjusted basis on April 5. As a result of the reverse stock split, the company's authorized common stock will decrease from 200,000,000 shares of common stock, with a par value of US$0.001 per share, to 13,333,333 shares of common stock, with a par value of US$0.001 per share, and the number of the company's issued and outstanding shares of common stock is expected to decrease from approximately 152,080,692 to approximately 10,138,713. Any fractional shares resulting from the reverse stock split will be rounded up to the next nearest whole number. The company's authorized preferred stock will not be affected by the reverse stock split and will continue to be 100,000,000 shares of preferred stock, with a par value of US$0.001 per share. The company is effectuating the reverse stock split to increase the per share trading price of the company's common stock in order to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

09:17 EDT Sanara MedTech receives 510(k) clearance for BIASURGE - Sanara MedTech has received 510(k) clearance for BIASURGE Advanced Surgical Solution.

09:16 EDT Illumina's NovaSeq X exceeds 200th order milestone in Q1 - Illumina announced it has already exceeded more than 200 orders for its revolutionary NovaSeq X sequencing system in the first quarter of 2023. The orders represent a diverse customer base spanning research and clinical customer segments in nearly 30 countries, across five continents, all seeking to add NovaSeq X - our fastest, most powerful, most sustainable high-throughput sequencer available.

09:12 EDT CNH Industrial announces subsidiary notes offering - CNH Industrial announced that its wholly owned subsidiary, CNH Industrial Capital LLC, plans to offer new notes, subject to market conditions. The notes will be guaranteed by CNH Industrial Capital America LLC and New Holland Credit Company, LLC, each a wholly owned subsidiary of CNH Industrial Capital LLC. CNH Industrial Capital LLC is the North American arm of CNH Industrial's global financial services business. CNH Industrial Capital LLC intends to add the net proceeds from the offering to its general funds and use them for working capital and other general corporate purposes, including, among other things, the purchase of receivables or other assets in the ordinary course of business. The net proceeds may also be applied to repay CNH Industrial Capital LLC's indebtedness as it becomes due.

09:10 EDT Taboola drives over 50% ROAS for Bombas - Taboola announced the results of successful advertising campaigns with comfort-focused apparel brand Bombas, dramatically increasing Return on Ad Spend, ROAS, by more than 50%. The success of the campaign is part of a long-term partnership between Bombas and Taboola. The teams also previously collaborated on a 2020 Pride Campaign, where Taboola helped amplify Bombas' Pride Collection by reaching more than one million people and driving tens of thousands of people to Bombas' landing page. "Bombas has a great cause and has been an important partner of ours. We're proud to be giving them the reach they need to make sure their message resonates," said Adam Singolda, Founder and CEO at Taboola. "This campaign shows that we're driving clear results for Bombas and I'm excited to continue our partnership."

09:09 EDT AMC Entertainment down after settlement with shareholders - Common stockholders of AMC Entertainment Holdings have reached an agreement with the company that will provide them additional shares as part of a recapitalization that "will afford AMC access to the equity it asserts it needs to service its debt obligations as it continues its recovery from the pandemic." The settlement, announced by lawyers representing the stockholder group, will grant holders of AMC common stock one share of common stock for every 7.5 shares held following a reverse stock split carried out in connection with a planned conversion of preferred share units, called APEs, into common stock. Any fractional shares owed will be paid in cash. "By providing meaningful consideration to common stockholders in exchange for the conversion and reverse split, the settlement will preserve over $100M of common stockholders' stake in the company. The settlement also will allow AMC to proceed with its recapitalization, which was designed to afford the company additional flexibility in paying down its debt, providing an important runway for the chain to manage its financial obligations in the long and short term. The settlement consideration, comprising approximately 6.9M post-reverse split shares, will be distributed to pre-conversion holders of AMC common stock. While the value of those shares at issuance will depend on market prices, their aggregate value is expected to exceed $100M based on recent trading prices of AMC equity. Stockholders brought suit in the Delaware Court of Chancery on February 20 against AMC and its board of directors, seeking a restraining order to block amendments to the company's charter that would have dramatically increased the number of authorized common shares and diluted existing common stockholders, without giving them any compensation in return. A hearing on the preliminary injunction had been scheduled for April 27. Absent this case and settlement, those amendments would have gone through without any additional consideration to common stockholders. The parties anticipate that the share distribution will be made approximately 10 trading days after the company files for stock exchange approval of the conversion and reverse split, which is expected to occur on Tuesday, April 4," lawyers from the firms said in a press release. In pre-market trading, AMC shares are down $1.18, or 23%, to $3.93.

09:08 EDT Progress Software releases Progress Sitefinity 14.4 - Progress announced the release of Progress Sitefinity 14.4. Progress Sitefinity is at the center of Progress' composable digital experience platform, which empowers organizations to create personalized digital experiences across multiple digital channels and drive effective digital transformation strategies. As digital interactions become the primary experience that customers have with brands, it is vital to gain a deeper understanding of behavioral patterns and utilize them to enhance digital experiences. The most recent release of Progress Sitefinity facilitates faster delivery of modern digital experiences through refined AI algorithms for improved understanding of customer behavior and segmentation, an upgraded .NET 7 frontend and the expansion of AI-based conversational interfaces with better context sensitivity. Additionally, Sitefinity 14.4 offers extended support timeframes to organizations.

09:07 EDT AMC sinks 23% to $3.91 after stock conversion suit settlement

09:06 EDT LiveOne regains compliance with Nasdaq listing requirements - LiveOne announced that on April 3, 2023, the company received formal notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that LiveOne has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notice indicated that as a result of the closing bid price of the Company's common stock having been at least $1.00 per share for a minimum required number of consecutive business days, LiveOne has regained compliance with Nasdaq Listing Rule 5550(a)(2) and advised that this matter is now closed.

09:05 EDT Philips, Northwell Health partner to standardize patient monitoring - Royal Philips announced they have entered into a seven-year agreement to help the health system standardize patient monitoring, enhance patient care and improve patient outcomes while driving interoperability and data innovation. "As forward-thinking health systems like Northwell Health take an enterprise-wide approach to healthcare IT, we can help take the guesswork out of the technology and help them to standardize their systems, with an open, interoperable architecture that can break down barriers to integration and simplify workflow for care providers," said Jeff DiLullo, chief market leader of Philips North America. "Their new patient monitoring system can help minimize manual tasks, give staff a centralized view of patients, and harness the power of massive amounts of data by using AI to provide actionable clinical insights - all of which are helping them to deliver a better patient and staff experience, lower costs and contribute toward the goal of improving outcomes."

09:04 EDT Clearwater Analytics names Scott Erickson as Chief Revenue Officer - Clearwater Analytics announced that Scott Erickson has been appointed as the company's first Chief Revenue Officer. He will now oversee Clearwater's sales efforts in Europe, Asia, and the Americas. With an 18-year track record of driving Clearwater's growth including roles in services, product strategy, and sales, Erickson will continue to lead the company's market share expansion, now across all regions.

09:03 EDT PayPal adds new features to complete payments solution - PayPal announced it has added new features to its complete payments solution for small businesses. The solution enables small businesses to accept a range of payments including PayPal, Venmo and PayPal Pay Later products. Giving customers more choice in how they can pay can help drive checkout. Fifty-nine percent of respondents of a recent Ponemon Institute study said their customers frequently abandon their shopping cart when their preferred payment method is unavailable. PayPal's complete payments solution also enables small businesses to process card payments directly on their website, and customize the checkout experience to match the look and feel of their brand, all through a single integration. Beginning today, PayPal will also give small businesses access to four new features to help them drive payment acceptance and enhance how they run their business. This will include Apple Pay as a checkout option2, the ability for customers to save payment methods with the PayPal vault for faster future checkout, real-time account updater to help customers keep their payment methods up to date, and access to IC++ pricing.

09:02 EDT Arthur J. Gallagher acquires Quality First Insurance, no terms disclosed - Arthur J. Gallagher & Co. announced the acquisition of La Vista, Nebraska-based Quality First Insurance. Terms of the transaction were not disclosed. Quality First Insurance is an insurance agency serving health care and senior living facilities in Nebraska and its surrounding states.

09:02 EDT Ericsson's Cradelpoint acquires Ericom Software - Cradlepoint, part of Ericsson, announced that it has acquired Ericom Software and their advanced enterprise cloud security platform to solidify Cradlepoint's SASE and zero trust offerings for hybrid 5G and wireline environments. The Ericom acquisition is a key part of Cradlepoint's strategy of building a full-stack enterprise security service optimized for 5G. Ericom's zero trust and cloud-based security solutions will form the basis of the new Cradlepoint NetCloud Threat Defense cloud service, expanding the company's mobile-capable and router-integrated SASE and zero trust portfolio of solutions for fixed-site, remote worker, in-vehicle and IoT use cases.

08:57 EDT Virgin Atlantic renews long-term global distribution agreement with Sabre - Sabre and Virgin Atlantic have reaffirmed their long-standing relationship with the renewal of their global distribution agreement. Under the expanded agreement, Sabre will now offer enhanced Virgin Atlantic content through its GDS marketplace, as well as the future ability to retail NDC offers. This will enable the hundreds of thousands of Sabre-connected agencies to have even richer access to Virgin Atlantic's broad range of products and offers.

08:54 EDT Bruush Oral Care appoints Mandeek Manhas as CFO - Bruush Oral Care has appointed Mandeek Manhas as the new CFO. Prior to joining Bruush, Mr. Manhas held leadership positions in two reputable organizations, including a private real estate company with over $2.5 billion in asset value and a publicly listed, multi-national mining company with advanced development stage and exploration projects.

08:52 EDT AIM ImmunoTech announces central IRB approval of Phase 2 study protocol - AIM ImmunoTech announced central Institutional Review Board approval for the protocol of its Phase 2 study evaluating Ampligen as a therapeutic for patients with post-COVID conditions. With this approval in hand, AIM is moving forward with the start-up process for the study's planned clinical sites. The AMP-518 clinical trial is a two-arm, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Ampligen in patients experiencing the post-COVID condition of fatigue. The primary outcome measure of the study is change from baseline to week 13 in PROMIS Fatigue Score. Other study outcomes include: change from baseline to week 6 in PROMIS Fatigue Score; change from baseline to weeks 6 and 13 in distance traveled during a Six-Minute Walk Test; proportion of subjects that surpass 54 meters in the Six-Minute Walk Test at the end of 12-week treatment phase; change from baseline to weeks 6 and 13 in PROMIS Cognitive Function Score; and change from baseline to weeks 6 and 13 in PROMIS Sleep Disturbance Score. AMP-518 is expected to enroll approximately 80 subjects between the ages of 18 to 60 years across up to 10 centers in the United States. Patients will be randomized 1:1 to receive twice weekly IV infusions of Ampligen or placebo for 12 weeks with a follow up phase of two weeks. The Company expects to begin patient enrollment and dosing in the AMP-518 study in Q2 2023.

08:49 EDT Avina Clean Hydrogen selects KBR for green ammonia project - Avina Clean Hydrogen has entered into an agreement with KBR for 2,200 metric tons per day of green ammonia plant in the U.S Gulf Coast. Under the terms of the agreement, KBR will provide the process technology license and engineering design for a grassroots project designed to produce 2,200 metric tons per day of green ammonia. The KBR process design encompasses a fully integrated plant, from electrolysis of water and air separation to ammonia synthesis, offering an end-to-end power to ammonia performance guarantee.

08:45 EDT Kalera PLC trading halted, news pending

08:44 EDT SG Echo to provide additional 90 units for approximately $6M - Safe & Green Holdings announced that SG Echo, a subsidiary of Safe & Green Holdings , has entered into an agreement to provide an additional 90 units for a private, long-standing client, with a price tag of roughly $6M. The order consists of 90 units which are part of an ongoing programmatic ordering process between the two companies. 80 of the units are a second product line from this client that fit into SG Echo's existing capacity and expertise in manufacturing. "It's very rewarding to see a relationship grow and expand the way it has with this client of ours," David Cross, Vice President of Business Development with Safe & Green Holdings Corp. noted. "As our clients transform themselves, we intend to support this evolution via our factory growth coupled with production enhancements. It is beneficial to be as nimble as we are; creating the solutions needed for our clients. This is a customer that really believes in us and has come to us with a variety of needs that we're happy to help with." The deliveries of the current set of units are anticipated to conclude in Q3 2023. The Company will provide further updates as appropriate on the current order, future orders and the evolving relationship with the private client.

08:40 EDT Veru announces preclinical results from expanded sabizabulin program - Veru announced results from a preclinical study of sabizabulin demonstrating robust anti-inflammatory activity with improved outcomes in an Influenza-Induced Pulmonary Inflammation Mouse Acute Respiratory Distress Syndrome, ARDS, Model. An animal study was conducted by a team of researchers at Labcorp Early Development Laboratories, Ltd, United Kingdom. Preclinical study results highlights: Sabizabulin treatment resulted in a statistically significant decrease in the total number of inflammatory cells in BAL fluid, including statistically significant reductions in both the innate and adaptive immune cells. In addition, sabizabulin treatment showed a statistically significant reduction in key cytokines and chemokines in BAL fluid that are part of the cytokine storm responsible for the acute lung injury: Keratinocyte-derived chemokine, Interleukin-6, TNF-alpha, Interferon-gamma, and CXCL-10. In contrast, dexamethasone treatment did not demonstrate a statistically significant reduction in the total number of inflammatory cells in the BAL fluid. Dexamethasone also had a different effect from sabizabulin on cytokine production in the BAL fluid. Dexamethasone treatment resulted in statistically significant reductions for IL-6 and INF-gamma, but no statistically significant changes for KC, TNF-alpha, and CXCL- 10. Clinically, sabizabulin treatment resulted in a reduction in the severity of lung inflammation and a dose-dependent improvement of lung function.The Company expects to submit the full data set for presentation in future scientific meetings and peer-reviewed publications.

08:39 EDT NFT Gaming provides update on game launches, AI, Gaxos Platform - The NFT Gaming Company is providing shareholders with an update on its roadmap for game launches, AI games, team expansion, as well as development and launch of its Gaxos Platform. On February 17, 2023, the Company closed on its Initial Public Offering. The Company sold 1,686,747 shares of Common Stock for aggregate gross proceeds of approximately $7 million before deducting offering expenses. The Company stock began trading on the Nasdaq Capital Market under the symbol "NFTG" on February 15, 2023. NFTG expects to begin launching its proprietary games on both Android and iOS by the end of the first half of 2023. The Company has approximately 12 games in various stages of development, with additional games to commence development shortly thereafter. Our current lineup features action, puzzle, strategy, multiplayer online battle arena, first-person shooters, and matching games. All of the games published by NFTG will be interconnected via the character/avatar and will possess the ability to transfer points and share economies. The Company has commenced building its AI-driven games by incorporating the most current AI technology such as OpenAI's, ChatGPT and GPT-4, and Midjourney. Management is assessing new AI technology for feasibility and value in developing its games. New products and developments in the space are currently occurring on a daily basis and the Company is intent on selecting the best technologies for its products. NFTG acquired Voxpow earlier this year to integrate certain AI features into its games. Voxpow boasts AI-powered speech-recognition technology with natural language processing that recognizes more than 100 languages and variants. Other features include sentiment analysis and a variety of other web-based integrations. ChatGPT and GPT-4 by OpenAI uses renowned language models designed to generate human-like conversations. The models are built on state-of-the-art AI technology and have been pre-trained on massive datasets, making it one of the most sophisticated language models in the market. The technology will enable The NFT Gaming Company to leverage these pre-trained models through APIs, making it easier to integrate into games to make interaction more realistic and engaging. Midjourney is a powerful artificial intelligence program that generates images from natural language descriptions called "prompts." The NFT Gaming Company will be able to create games where art is generated based on the choices that gamers will make while playing the games, potentially making each experience unique. Concurrently with the development of its games, NFTG is building its Gaxos platform that is expected to launch by the end of 2023. Gaxos will host all of NFTG's proprietary games as well as games owned and operated by third parties. The platform will feature a storyline that connects all of the games and characters. The Gaxos community of users will be able to participate in individual and platform-wide goals and achievements. Players will have the ability to mint an NFT of their avatars if they choose to take their character and progress off the platform. Users will be able to sell their NFT on a third-party platform and the new owner can experience Gaxos starting where the seller left off. In addition to the functional use of the NFT, users are able to mint for the collectability and ownership of their avatar. The Company is working with game developers, artists, back-end developers, and other professionals in South America, Eastern Europe, and various other locations worldwide. Management is committed to hiring the best talent while being mindful of the Company's resources. Management is actively hiring for roles needed to achieve its goals. On August 29, 2022, NFTG entered into a software and patent license agreement with Columbia University in the City of New York pursuant to which Columbia University granted us a royalty-bearing, exclusive, worldwide, non-transferable license to certain intellectual property solely for computer gaming for entertainment purposes involving non-fungible tokens. Management is committed to protecting its IP and will continue to explore additional methods of security in order to prevent any manipulation of its NFTs.

08:37 EDT Argo Blockchain mined 161 bitcoin in Marchat 5.2 BTC per day - The company states: "During the month of March, Argo mined 161 Bitcoin or Bitcoin Equivalents, together, BTC, or 5.2 BTC per day. This is a decrease of 10% over the 5.7 BTC per day produced in February 2023. The primary driver of the decrease in daily BTC production was the increase in network difficulty. In March, the average network difficulty was 11% higher than in February. As of 31 March 2023, the Company held 85 Bitcoin or Bitcoin Equivalents. The Company's total hashrate capacity continues to be 2.5 EH/s. Based on daily foreign exchange rates and cryptocurrency prices during the month, mining revenue in March amounted to $4.05M."

08:36 EDT Argo Blockchain names Jim MacCallum as new CFO effective April 5 - Argo Blockchain announces the appointment of Jim MacCallum as CFO. He will start in the position on 5 April 2023. Mr. MacCallum is not a statutory director of the Company. He currently serves as Chief Financial Officer of East Side Games Group Inc, a publicly-traded mobile game platform technology company based in Canada.

08:35 EDT Genasys receives IMNS order for large entertainment venue - Genasys announced a new Integrated Mass Notification System, IMNS, order for a large outdoor tourist destination. "Voice broadcast clarity, multiple activation and control options, and the ability of our IMNS installations to blend into the venue's layout and architecture were key considerations in securing this order," said Richard Danforth, Chief Executive Officer, Genasys Inc. "IMNS is one of the core components of Genasys Protect, our unified platform that empowers organizations with comprehensive emergency management and multichannel communications solutions that help safeguard people throughout crisis situations." Danforth added, "Our proven use cases from targeted verticals that include large entertainment venues, critical infrastructure protection, energy, utilities, and heavy manufacturing are creating greater awareness of our unified protective communications platform and accelerating pipeline growth."

08:34 EDT Nogin down 60% at $2.6 after pricing offering - Shares of Nogin are down 60% or $3.91 at $2.60 in pre-market trading after the company priced its $22M public offering at $3.00 per share. Shares of Nogin were up 139% yesterday.

08:34 EDT IDT Corp's net2phone enters partnership with Bridgepointe - net2phone, a subsidiary of IDT Corp, announced a strategic partnership with Bridgepointe, a leading tech advisory firm. Through the partnership, Bridgepointe will now offer its mid-market and enterprise clients net2phone's cloud communications solutions to enhance user experience across channels. "We are pleased to add net2phone to our lineup of suppliers," shared Gary Jacobs, Vice President, Operations and Sales Programs, Bridgepointe Technologies. "With their unified communications and collaboration capabilities our clients will have a powerful way to reduce costs while working smarter. With a full suite of UCaaS features and integration with applications such as Teams, net2phone is an ideal choice for reliable, seamless communication."

08:33 EDT ClearSign announces burner sale into Texas gulf coast market - ClearSign Technologies announces the first sale of its fire tube boiler burner technology into a non-boiler heater of a global chemical company in the Texas market. The boiler burner will be installed into a process heater, which is replacing an existing heater and SCR system. Both heater and burner were sold by Tulsa Heaters Midstream, a fast growing and innovative heater provider based in Tulsa, Oklahoma. The burner is scheduled to be installed in the third quarter of 2023.

08:32 EDT Ryman Hospitality announces 2023 board of directors slate - Ryman Hospitality Properties announced its slate of director nominees for its upcoming 2023 annual meeting of stockholders. The slate consists of the Company's nine incumbent directors and new director nominee William Haslam, the former Governor of the State of Tennessee from 2011 to 2019. Governor Haslam joins the following incumbent members of the Ryman Hospitality Properties Board as nominees for director at the 2023 annual meeting: Rachna Bhasin, Founder/CEO, EQ Partners; Alvin Bowles Jr., Global VP, Partnerships & Business Engineering, Meta Platforms, Inc.; Mark Fioravanti, President & Chief Executive Officer, Ryman Hospitality Properties, Inc.; Fazal Merchant, Private Consultant; Patrick Moore, Former EVP, North American Retail, Carter's, Inc.; Christine Pantoya, Chief Commercial Officer & Head of Strategy, FANchise; Robert Prather Jr., President & CEO, Heartland Media, LLC; Colin Reed, Executive Chairman, Ryman Hospitality Properties, Inc.; Michael Roth, Non-Executive Chairman, Pitney Bowes, Inc.

08:31 EDT Inozyme reports inducement grants under Nasdaq listing rule - Inozyme Pharma announced the grant of an inducement award outside of the Company's 2020 Stock Incentive Plan to its newly appointed Chief Operations Officer, Matthew Winton, Ph.D. The inducement award was approved by the Board of Directors effective as of April 3, 2023, pursuant to the Company's 2023 Inducement Stock Incentive Plan, as an inducement material to Dr. Winton entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant is a nonstatutory option to purchase up to 250,000 shares of the Company's common stock, at an exercise price of $5.39 per share, the closing price per share of the Company's common stock as reported by Nasdaq on April 3, 2023.

08:28 EDT New Relic to incur $40M-$45M in restructuring charges - In a regulatory 8-K filing last night, the company stated: "On March 29, 2023, the Board of Directors of New Relic committed to a restructuring plan in connection with reduction of its global real estate footprint in line with its Flex First philosophy. The Company expects to incur aggregate restructuring charges totaling approximately $40 million to $45 million, consisting primarily of real estate lease termination and other associated costs. The Company believes these initiatives will provide further operating flexibility and position the business for its long-term success. The Company expects approximately 65% of these charges will be non-cash charges, with the remainder as cash expenditures, and that it will recognize the majority of these restructuring costs in the fourth quarter of fiscal 2023."

08:27 EDT Avid Bioservices unveils completed mammalian cell facilities expansion - Avid Bioservices announced the completion of two expansions within the company's mammalian cell facilities. The company expects that the first customer for the newly expanded CGMP mammalian cell suites will begin manufacture this month. To celebrate the launch of the newly expanded facilities, Avid is today hosting an open house and tour for existing and prospective clients."We are proud to unveil our completed expansions and excited to kick off the first customer project within our latest, state-of-the-art mammalian cell manufacturing suites. These build-outs involved great complexity and required exemplary efforts from our entire team. I would like to acknowledge the tremendous work from everyone who played a role in completing these significant projects on schedule," said Nick Green, president and chief executive officer of Avid Bioservices. "This launch could not be timed any better based on the significant demand we continue to see for our mammalian cell services, highlighted by significant new business wins and the largest backlog in the history of the company." In addition to the launch of the newly expanded Myford facility, Avid also announced the completion of its mammalian cell process development expansion, which has doubled the company's total process development capacity. Now operational, these new capabilities have the potential to support up to an additional $25 million in annual process development revenue.

08:25 EDT NFI Group says CAVForth autonomous bus service will begin May 15 - NFI Group subsidiary Alexander Dennis announced that the CAVForth autonomous bus service in East Scotland will begin on May 15, 2023, using five Alexander Dennis Enviro200AV buses. CAVForth is a joint project of Fusion Processing Ltd, Stagecoach, Alexander Dennis, Transport Scotland, Edinburgh Napier University and Bristol Robotics Lab which is part funded by the UK Government's Centre for Connected and Autonomous Vehicles. It is one of the most complex projects of its kind worldwide and will be the first registered service in the UK to use full-sized autonomous buses.

08:23 EDT Labrador Gold announces results of annual general meeting - Labrador Gold announced results of its annual general meeting of shareholders held in Toronto on April 3, 2023. At the meeting shareholders re-elected five current directors, being Roger Moss, James Borland, Trevor Boyd, Leonidas Karabelas and Kai Hoffmann and approved the re-appointment of DeVisser Gray LLP, of Vancouver, British Columbia, as auditors of the Corporation. Shareholders also ratified the 2021 Stock Option Plan and approved the Corporation's new 2023 Stock Option Plan which supercedes and replaces the 2021 Stock Option Plan. Following the shareholder meeting the Board of Directors reconstituted its Audit Committee and also reappointed officers for the ensuing year as follows: President and CEO: Roger Moss; CFO Eric Myung; Corporate Secretary: William Johnstone. The Company also announces that in accordance with its Stock Option Plan, it has granted officers, directors, consultants and employees an aggregate of 3,100,000 incentive stock options exercisable until April 3, 2028 at $0.23 per share. The options will vest according to the following schedule, 20% on August 3, 2023, 20% on October 3, 2023, 20% on April 3, 2024, 20% on October 3, 2024 and 20% on April 3,2025.

08:22 EDT Rafael Holdings announces up to $5M share repurchase program - Rafael Holdings announced that its Board of Directors has authorized the repurchase of up to $5M of the Company's Class B common stock.

08:20 EDT Amarin announces VAZKEPA approved by Israel's MOH - Amarin announced that Israel's Ministry of Health, MOH, Pharmaceuticals Division has granted regulatory approval to VAZKEPA. The MOH issued its approval of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides and either established cardiovascular disease or diabetes and at least one other cardiovascular risk factor. "The regulatory approval of VAZKEPA in Israel marks continued progress in our effort to bring this product to patients with residual cardiovascular risk around the world," said Steven Ketchum, PhD., President, Research & Development and Chief Scientific Officer, Amarin. "We are proud of this important milestone in that effort, and that patients in Israel may soon be able to access this important therapeutic option to address their residual cardiovascular risk." Amarin has partnership discussions underway in this territory and will be preparing for potential pricing and reimbursement in Israel beginning in 2024.

08:19 EDT SAB Biotherapeutics announces appointment of Lucera to board of directors - SAB Biotherapeutics announced the appointment of Erick Lucera, CFA, a veteran of the biotechnology and medical device industry, with over thirty years of financial, operational and investment experience, to SAB's Board of Directors, effective April 4, 2023. Most recently, Lucera served as chief financial officer for AVEO Oncology.

08:16 EDT iCAD announces publication of clinical data for ProFound AI Risk - iCAD announced new clinical evidence published in the Journal of Clinical Oncology found ProFound AI Risk for 2D Mammography is more accurate than Tyrer-Cuzick v8, a commonly used lifestyle risk model, for both short-term and long-term risk assessments. Using the unique KARolinska MAmmography Project for Risk Prediction of Breast Cancer screening cohort, researchers compared ProFound AI Risk with Tyrer-Cuzick v8 in a case-cohort study of 8,604 women aged 40-74 years throughout a 10-year follow up. ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women - regardless of menopausal status, breast density, and family history of breast cancer - with an area under the curve ranging from 0.74-0.65 for ProFound AI Risk, compared to 0.62-0.60 for Tyrer-Cuzick v8. iCAD's Breast AI Suite offers a 360-degree solution of clinically proven cancer detection, density assessment, and risk evaluation technologies. The latest addition to iCAD's Breast AI Suite, ProFound AI Risk, is the world's first clinical decision support tool that provides an accurate short-term breast cancer risk estimation that is truly personalized for each woman, based only on her mammogram.6,7 Available for both 2D and 3D mammography, it uniquely combines age, breast density and subtle mammographic features, offering superior performance and accuracy in assessing short-term risk compared to traditional, commonly-used breast cancer risk models. ProFound AI Risk complements traditional risk models and is easy for clinicians and medical facilities to adopt, as it only requires the images from a 2D or 3D mammogram, with no questionnaires, portals, or staff required to implement.

08:14 EDT Nexcella to present updated NXC-201 clinical data at EBMT meeting - Nexcella announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation to be held in Paris, France, 23-26 April 2023. Posters to be presented: Title: "Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center" / Nexcella, Inc. previously announced that NXC-201 produced a 90% overall response rate and 59% complete response/stringent complete response at the therapeutic dose from the first 42 patients in an ongoing phase 1b/2a relapsed/refractory multiple myeloma ongoing clinical trial as of the October 23, 2022 data cutoff. NXC-201 also produced 100% hematologic complete response rate and 100% organ response rate in 5 relapsed/refractory AL Amyloidosis patients as of the October 23, 2022 data cutoff. Low-grade CRS duration of median 2 days with median onset of 1-day post-dosing at therapeutic dose in relapsed/refractory multiple myeloma points to NXC-201 potentially becoming the first and only out-patient CAR-T for Multiple Myeloma, AL Amyloidosis and other BCMA-positive malignancies.

08:12 EDT Montrose Environmental appoints John Jackson as Chief Information Officer - Montrose Environmental Group announced the appointment of information technology veteran John Jackson as Chief Information Officer, effective immediately. He will report directly to Montrose President and Chief Executive Officer, Vijay Manthripragada, and join the Company's Executive Leadership team.

08:12 EDT Bullfrog AI announces licensing agreement with Johns Hopkins - BullFrog AI Holdings announcee its worldwide license agreement with Johns Hopkins University Applied Physics Laboratory for use of patented technology powering the Company's bfLEAP platform. BullFrog's bfLEAP platform analyzes drug development data to potentially make life-saving therapies and treatments available to patients more quickly. The patented technology from APL includes analytical models that enable the analysis and interpretation of large, complex, and diverse datasets that may be incomplete and comprise both numerical and categorical data and provide explainable results. The innovative technology, which enables the detection of anomalies, patterns, and relationships, has been shown to perform better than well-known algorithms in benchmarking tests. BullFrog AI is deploying bfLEAP for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need. The licensed technologies from APL include Prometheus and Seagull. Prometheus includes a comprehensive library of APL-invented probabilistic models, one of which recently beat 10 competing algorithms in detecting anomalies in an extensive benchmarking study done using 12 open-source data sets. Prometheus also includes graph algorithms that have been successfully used to analyze large-scale network resilience problems on multimodal global networks, such as global logistics and communication networks.

08:09 EDT electroCore announces gammaCore Sapphire available through Carrick Institute - electroCore announced that the gammaCore Sapphire non-invasive vagus nerve stimulator will be available for purchase by clinicians through the Carrick Institute for Graduate Studies which provides clinical neuroscience education.

08:08 EDT JetBlue enter technology collaboration with Shift5 - Shift5 announced its partnership with JetBlue to bring cybersecurity and data observability of onboard avionics to commercial aircraft. The company also welcomes JetBlue Ventures as an investor in its Series B round of funding, which was led by Insight Partners with participation from The Boeing Company and AE Industrial Partners' AEI HorizonX. The investment from JetBlue Ventures enables Shift5 to develop new platform capabilities that will improve the efficiency and safety of commercial air travel.

08:07 EDT Absci partners with M2GEN to accelerate drug creation for oncology - Absci Corporation and M2GEN announced a partnership to create new cancer medicines and bring them to market at unprecedented speed. Absci's generative AI drug creation platform will tap into M2GEN's clinical and molecular data set, ORIEN AVATAR, to accelerate the creation of therapeutics for a range of malignancies and patient profiles, bringing AI drug creation to the fight against cancer. A key challenge in creating effective cancer treatments is finding specific antigens that can be targeted by immunotherapies. M2GEN's AVATAR database represents a valuable resource for discovering such antigens. Absci will use its reverse immunology technology to first search the database for antibodies from patients with exceptional immune responses, then computationally re-assemble antigen-antibody pairs as promising starting points for drug development. This partnership brings together AI drug creation technology and oncology bioinformatics to potentially reduce the time and cost to create better cancer treatments. Absci's Integrated Drug Creation platform unites generative AI and wet-lab capabilities to screen billions of cells per week, allowing it to go from AI-designed antibodies to lab-validated candidates in as little as six weeks. As the nexus between patients, researchers, and the pharmaceutical industry, M2GEN is uniquely positioned and equipped with the richest clinicogenomic data set, and a lifetime patient-consented Total Cancer Care protocol, to accelerate drug discovery and development and transform how cancer is treated. M2GEN's real-world data set comes from its Oncology Research Information Exchange Network partners, an alliance of 18 cancer centers across more than a dozen U.S. states.

08:06 EDT Seelos Therapeutics doses first ALS patient with SLS-005 - Seelos Therapeutics announced it has dosed the first patient in an Expanded Access Program for patients with ALS who do not qualify for existing clinical trials and that the EAP will be fully funded by a grant from the NINDS under the ACT for ALS. Under this EAP, Seelos plans to initially enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS in parallel to its ongoing, fully enrolled, randomized double-blind placebo-controlled Phase II/III study on the HEALEY ALS Platform.

08:05 EDT Ceridian reports over $1B in earned wages delivered through Dayforce Wallet - Ceridian announced continued momentum for Dayforce Wallet with more than $1 billion in earned wages delivered to users since launching in 2020. This growth is supported by research showing the product's strong appeal to both employees and employers, with more than 1,450 organizations - including David's Bridal, OTG Management, and The Budd Group - signed up to use Dayforce Wallet for on-demand pay. Dayforce Wallet allows workers to access their earned wages any time, which is a critical workplace benefit for employees needing to manage daily expenses or unexpected bills in between pay periods. The modern pay experience resonates with employees, with the typical user conducting 25 transactions per month on average.

08:04 EDT Papa John's and PJP Investments team on 650 new restaurants in India by 2033 - Papa John's International announced an expanded partnership with PJP Investments Group , one of Papa Johns longest-tenured international franchisee partners, to open 650 restaurants in India by 2033. The first of these new restaurants is scheduled to open in 2024 in Bangalore, followed by openings in other cities in South India and then across other regions of the country. India is an attractive market for Papa Johns, given the country's significant size, as well as the burgeoning income and rising aspirations of its middle class. "Papa Johns global momentum continues, in partnership with seasoned, successful restaurant operators like PJP Investments," said Amanda Clark, Papa Johns Chief International and Development Officer. "PJP Investments first partnered with Papa Johns to expand into the UAE in 2005. We are excited that their commitment to flawless execution of Papa Johns high standards is now being brought to India." PJP Investments Group, which currently operates more than 100 Papa Johns restaurants across the UAE, Saudi Arabia and Jordan, will open the first Papa Johns location in Iraq in 2024. Lead by CEO Tapan Vaidya, PJP is among the first Papa Johns international franchisees to adopt a new, more modern design for international restaurants that is elevating the Papa Johns experience around the globe. About Papa Johns

08:04 EDT Arko's GPM Investments launches upgrade to fas REWARDS app - GPM Investments announced the launch of its new fas REWARDS app. The new app is available in the APP Store and in Google Play and offers enrolled loyalty members a variety of new features, including exclusive in-app member only HOT deals not available in stores, order and delivery, age verified offers on tobacco and alcohol, a store locator with current gas prices at GPM stores close to members, and much, much more. Key features of the new fas REWARDS app include: Exclusive in-app HOT deals, which provide enrolled fas REWARDS loyalty members who use the app with additional savings throughout the year. As an example, this week members can get a free 5 Hour Energy. Virtual wallet, which helps to keep user engagement up as they browse and add exclusive offers to their wallet. Geo-fenced location, which leverages the user's location services allowing them to access the app from any one of GPM's community brands. fas REWARDS Dashboard, which enables further personalization by presenting the member's reward balances, and incentivizes them to reach their next "redemption goal." Order and delivery or pickup, which allows customers to conveniently order ahead and has provided a new revenue stream adding incremental sales to 1,233 locations. Referral program, which rewards users for inviting friends and family to enroll in the fas REWARDS loyalty program. Both parties will receive $5 in fas BUCKS upon successfully enrolling.

08:03 EDT Caribou Biosciences announces FDA granted FTD to CB-011 - Caribou Biosciences announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to CB-011, which is being developed for relapsed or refractory multiple myeloma. CB-011 is being evaluated in the company's ongoing CaMMouflage Phase 1 clinical trial in patients with r/r MM. "Fast Track designation for CB-011 allows us instrumental interactions with the FDA as we progress our clinical development and regulatory plans for CB-011. This designation could not be more timely as we recently dosed our first patient in the CaMMouflage Phase 1 trial," said Syed Rizvi, MD, Caribou's chief medical officer. "Our goal is to develop CB-011 as a readily available off-the-shelf treatment option for patients with relapsed or refractory multiple myeloma to overcome the need for apheresis or bridging therapy, variable quality and long manufacturing timelines, manufacturing failures, or the inability to bear the burden of treatments that require frequent dosing over several months."

08:02 EDT GrowGeneration acquires inventory, equipment from Community Garden & Greenhouse - GrowGeneration announced the acquisition of inventory and equipment from Community Garden & Greenhouse, a provider of hydroponics and garden supplies to the broader Bozeman, Montana growing market. As a part of the transaction, GrowGen also took over the existing store location at 1602 W. Beall St.

07:59 EDT Maris-Tech chosen by governmental agency for Jupiter Automotive solution - Maris-Tech has been selected by a governmental agency to develop and deliver the Jupiter Automotive, a Home Land Security, automotive related, video solution based on the Company's Jupiter platform. This solution will become a technology enabler for a variety of automotive applications in the defense, HLS and commercial markets. The order is in the amount of $100,000 and it is expected to be delivered to the customer during the year 2023.

07:47 EDT NanoViricides signs license agreement with Karveer Meditech - NanoViricides has executed a License Agreement with Karveer Meditech. Under this Agreement, Karveer has the right to commercialize the Company's COVID drugs NV-CoV-2 and NV-CoV-2-R in India. To enable commercialization, Karveer has undertaken Clinical Development and Evaluation and is sponsoring these two drugs in India for this purpose. Karveer has represented to NanoViricides that it has successfully obtained required regulatory permissions to conduct clinical evaluation of NV-CoV-2 as a COVID treatment in India. Under the License Agreement, NanoViricides has granted Karveer a limited, non-transferable, exclusive license for commercialization of NV-CoV-2 and NV-CoV-2-R in India. Karveer will conduct clinical evaluation of the drugs as necessary in adherence with regulations in India, including ICH guidelines, as a part of its development and commercialization efforts in India. NanoViricides will have full rights to the data generated in the clinical trials, and may use this data internationally as needed. For this purpose, NanoViricides will reimburse Karveer for all direct and indirect costs and a development fee of 30% of such costs, and any applicable taxes. Upon commercialization, NanoViricides will receive a royalty of 70% of final invoiced sales. Previously, on September 15, 2021, NanoViricides signed a Master Services Agreement with Karveer in which Karveer declared its intent to license NV-COV-2 and NV-CoV-2-R for commercialization in India, and undertook the responsibility to obtain necessary licenses and regulatory approvals as would be needed for the clinical evaluation and commercialization of the drugs in India. No binding licensing activity took place under that earlier agreement.

07:44 EDT ARway unveils ARwayKit SDK Version 2.3 - ARway.ai announce the release of ARwayKit SDK Version 2.3, packed with significant upgrades and improvements aimed at enhancing AR experiences for users and expanding opportunities for developers. The updated SDK brings several new features, including: Image Access Points: Easily activate AR Maps and experiences by scanning images, streamlining the user experience and increasing engagement. Videos as spatial content in AR: Enhance AR experiences by incorporating video content, providing richer and more immersive interactions. Advanced content occlusion: Improved depth perception and realism in AR scenes, creating more believable and engaging experiences. Custom Branding Watermark: Enable developers to incorporate their branding into AR experiences, promoting brand recognition and affinity.Updated relocalization method with background tracking: Improved tracking accuracy and stability, ensuring a more seamless and reliable user experience. Access to Analytics Suite: Empower developers with valuable insights into user behavior and engagement, driving data-driven decisions and optimizations. Relocalization notifications: Alert users in case of significant drift, ensuring a consistent and accurate AR experience.

07:42 EDT Titan Medical announces receipt of management cease trade order - Titan Medical announces that it has been granted a management cease trade order by the Ontario Securities Commission, as its principal regulator, under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults. On March 22, 2023, the Company announced that it would not be filing its annual financial statements, the related management's discussion and analysis and annual information form, and the accompanying chief executive officer and chief financial officer certification for its financial year ended December 31, 2022 within the time period prescribed by National Instrument 51-102 - Continuous Disclosure Obligations and National Instrument 52-109 - Certification of Disclosure in Issuers' Annual and Interim Filings; and it had applied to the Ontario Securities Commission requesting a MCTO be imposed in respect of the late filing of its Annual Filing Documents. The MCTO restricts all trading in and all acquisitions of the securities of the Company, directly or indirectly, by the Chief Executive Officer and the Chief Financial Officer of the Company until two full business days following the receipt by the OSC of the Annual Filing Documents and any other filings the Company is required to make under Ontario securities laws, or upon the further order of the director of the OSC. The MCTO does not affect the ability of shareholders who are not named in the MCTO to trade their securities. During the period that the MCTO is in effect, the Company intends to satisfy the provisions of section 10 of NP 12-203 and issue bi-weekly default status reports. As announced on March 22, 2023, the Company confirms that it has filed a Form 25 with the U.S. Securities and Exchange Commission. The Company expects its reporting obligations under Section 12(b) of the Exchange Act to be suspended on or about April 14, 2023. The Company confirms that it is not subject to any insolvency proceedings at this time and that there is no other material information concerning its affairs that have not been generally disclosed.

07:40 EDT Mosaic congratulates Patriot Battery Metals on recet drilling results - The company said, "Mosaic Minerals Corporation would first like to congratulate the management of Patriot Battery Metals for the success it is achieving in the development of its Corvette project, in James Bay. Recent drilling results continue to demonstrate the importance of this project, which could eventually lead to a major lithium deposit. Mosaic, through its Pluton SM project located on the eastern edge of the Corvette project, is very pleased to be able to actively participate in the development of this strategic territory with a first phase of work including exploration and ground sampling. The potential targets were defined by the various compilation works carried out in collaboration with ALS Goldspot. This work will begin as soon as access conditions are favorable to the deployment of work teams on site."

07:39 EDT Midland enters binding term sheet to option Patris property to Barrick Gold - Midland Exploration announced the signing of a binding term sheet with a wholly-owned subsidiary of Barrick Gold whereby Barrick will have the right to earn into Midland's wholly-owned Patris gold property, located approximately 30 kilometres to the northeast of the town of Rouyn-Noranda, Quebec. Pursuant to the Transaction, Barrick has the right to acquire up to a 75% interest in the Patris property in consideration for cash payments totalling C$1,017,500 and exploration work totalling C$16,575,000, over an eight-year period, including a guaranteed amount of C$3,000,000, over a four-year period. Barrick will be the operator of the work carried out under the Transaction. Midland and Barrick have agreed to negotiate a definitive earn-in and joint venture agreement, which is subject to customary terms and conditions as set forth in the term sheet, including the successful negotiation and execution of a definitive agreement for the Transaction, the satisfactory completion of due diligence by Barrick and the receipt of any required regulatory approvals.

07:38 EDT Biogen appoints Keeney as Head of Corporate Development - Biogen announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen's Executive Committee reporting to Christopher Viehbacher, President and Chief Executive Officer. Dr. Keeney brings more than 20 years of experience leading R&D, business development and strategy organizations at industry-leading companies within biotech and large pharma, most recently as the Chief Executive Officer of NodThera.

07:37 EDT Shyft Group achieves CARB approval for Blue Arc EV delivery vehicles - The Shyft Group announced it has completed testing and received an executive order of compliance from the California Air Resources Board, CARB, for the Company's Blue Arc EV Solutions Class 3, 4 and 5 electric delivery vehicles. Within the executive order, CARB confirmed the city driving range of 225 miles for the Class 3 Blue Arc EVs under CARB test conditions, including three models offering 600, 700 or 800 cubic feet of cargo capacity. The Class 4 and 5 EVs provide 700 to 1,000 cubic feet. "This is an important, validating step for the Blue Arc Class 3, 4 and 5 all-electric delivery vehicles that were designed from the ground up by applying 50 years of experience in the last mile delivery space," said Daryl Adams, President and CEO, The Shyft Group. "It shows our commitment to providing a robust EV solution that meets the clean air requirements in every state and supports a greener future."

07:34 EDT Vision Marine Technologies names Murray as Chairman - Vision Marine Technologies announces the appointment of Carter Murray as Chairman of the Company's board of directors. Murray will work directly with Vision Marine's Chief Executive Officer, Alex Mongeon, to continue transforming recreational boating through innovation, technology and superior performance with the Company's leading powertrain technology and outboard electric engines.

07:33 EDT Zevra Therapeutics submits IND for KP1077 in narcolepsy - Zevra Therapeutics announced the submission of an Investigational New Drug application seeking authorization from the U.S. Food and Drug Administration to begin a Phase 1 clinical trial of KP1077 in narcolepsy. Once the clinical investigation plan proposed in the IND has been cleared to proceed by the FDA, Zevra plans to initiate its first of several Phase 1 clinical trials of KP1077 as early as the second quarter of 2023. KP1077 is also currently being evaluated in a Phase 2 clinical trial for the treatment of idiopathic hypersomnia. Those data have the potential to support not only the advancement of KP1077 into a pivotal Phase 3 study in IH, but also a Phase 3 trial in narcolepsy. Zevra filed an IND application in May 2022 for the treatment of IH with KP1077 and subsequently initiated a Phase 2 IH study in December 2022. During a pre-IND meeting with the FDA, Zevra received confirmation that additional non-clinical studies were not needed to advance KP1077 into clinical development due to the abundance of data already available on serdexmethylphenidate.

07:31 EDT W.P. Carey announces $468M industrial portfolio investment in Canada - W. P. Carey announced the approximately $468M sale-leaseback of a critical portfolio of four pharmaceutical R&D and manufacturing campuses with Apotex Pharmaceutical Holdings, a global pharmaceutical company and the largest generic drug manufacturer in Canada. The portfolio represents the vast majority of Apotex's global operations, comprising 11 properties covering 2.3M square feet spread across four campuses located in attractive industrial submarkets within the Greater Toronto Area. Structured as a triple-net master lease with rent payable in U.S. dollars and fixed rent escalations over a 20-year term, the sale-leaseback transaction closed concurrently with private equity firm SK Capital's majority buyout of Apotex, financing a portion of the buyout.

07:26 EDT Laser Photonics adds Korn Ferry, Direct Recruiters to identify sales candidates - Laser Photonics announced it has added Korn Ferry and Direct Recruiters, Inc. to identify qualified sales candidates with experience selling into defense companies and the U.S. military.

07:23 EDT Silver Tiger Metals announces drill results from Sulphide Zone - Silver Tiger Metals has intersected 1,156.4 g/t total silver equivalent over 2.0 meters in the Sulphide Zone in Drill Hole ET-23-446 from 390.5 meters to 392.5 meters, consisting of 666.2 g/t silver, 0.17 g/t gold, 0.93% copper, 4.26% lead and 8.67% zinc within 17.9 meters grading 425.9 g/t total silver equivalent from 382.8 meters to 400.7 meters consisting of 200.7 g/t silver, 0.19 g/t gold, 0.42% copper, 2.23% lead and 3.55% zinc in the Sulphide Zone. Highlights from the on-going drilling program include the following: Hole ET-23-445: 1.6 meters grading 1,269.6 g/t total silver equivalent from 467.0 meters to 468.6 meters, consisting of 441.7 g/t silver, 0.59 g/t gold, 2.14% copper, 7.58% lead and 12.0% zinc within 9.6 meters grading 364.6 g/t total silver equivalent from 465.0 meters to 474.6 meters consisting of 115.1 g/t silver, 0.24 g/t gold, 0.58% copper, 1.98% lead and 3.88% zinc in the Sulphide Zone. Hole ET-23-448: 1.0 meters grading 1,285.5 g/t total silver equivalent from 254.9 meters to 255.9 meters, consisting of 1,194.5 g/t silver, 0.04 g/t gold, 0.84% copper, 0.03% lead and 0.19% zinc within 4.9 meters grading 521.7 g/t total silver equivalent from 253.0 meters to 257.9 meters consisting of 484.8 g/t silver, 0.03 g/t gold, 0.33% copper, 0.01% lead and 0.08% zinc in the El Tigre Vein Zone.

07:19 EDT BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees stock options to purchase an aggregate of 124,300 shares, and restricted stock units (RSUs) covering an aggregate of 40,350 shares, of BioCryst common stock. The options and RSUs were granted as of March 31, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $8.34 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

07:18 EDT Colliers International issues notice of redemption for convertible notes - Colliers International Group announced that it has issued a notice of redemption to all holders of its previously issued 4.00% convertible senior subordinated notes due 2025. As at the date hereof, $230M of principal amount is outstanding pursuant to the Convertible Notes. The applicable redemption date shall be June 1, 2023, and Colliers will, in accordance with the terms and conditions of the indenture governing the Convertible Notes, satisfy its obligations in connection with any redeemed Convertible Notes by issuing an amount of subordinate voting shares per $1,000 of redeemed principal amount that is calculated based on the average of daily volume-weighted average trading prices of the Shares for the thirty trading day period ending on May 24, 2023. All accrued but unpaid interest on any redeemed amounts for the period up to but excluding the Redemption Date will be paid in cash. Prior to 5:00 p.m. on May 31, 2023, holders of Convertible Notes will have the right to convert into Shares at a conversion rate of 17.7607 Shares per $1,000 of principal amount, which is equivalent to a conversion price of approximately $56.30 per Share.

07:16 EDT Flora Growth launches prescription cannabis medicines in Colombia - Flora Growth announced the certification of its Bogota-based compound formulation laboratory, Flora Lab 4, following the required regulatory inspection by INVIMA Colombia's FDA . The inspection certifies the lab as meeting Current Good Manufacturing Practices standards as determined by INVIMA. Flora Lab 4 specializes in manufacturing compound formulations utilizing cannabis derivatives and traditional master formulas. Flora Lab 4 will now begin offering its cannabis formulations as well as design, development and manufacturing services for third parties. The lab will also make available to clients its experienced team members, knowledge of cannabis and modern facilities to promote the growth of the medical cannabis sector. To begin, the team has developed eight cannabis-based formulations, in both topical and ingestible formats, specially designed to aid in the treatment of specific ailments, including various skin conditions, multiple sclerosis, anxiety and dementia. The team hopes to gather patient-reported pilot-study data to better understand patient responses and outcomes. "We are very pleased to have received CGMP certification and to bring effective medicinal cannabis treatments to patients in Colombia. We applaud the Colombian government's acknowledgment of the power of this plant by requiring all health insurance providers to cover the cost of medical cannabis. This policy is fundamental to fair access to these medicines for Colombia's roughly 30 million eligible patients," said Luis Merchan, Chairman and CEO of Flora. "At Flora, we know the future of cannabis relies heavily on the transformation of this unique plant into mainstream medicines, accessible to the populations who need it most. We are proud to be playing a leading role in the progress toward that goal." With the approval from INVIMA, cannabis medicines can now be accessed by doctor networks throughout Colombia and can immediately be prescribed to patients over the age of 18. This offering comes as a law that went into effect on January 1, 2023, requires all insurance providers in the country to cover the cost of medical cannabis treatments for patients.

07:14 EDT Silence announces publication demonstrating role for iron regulation in PV - Silence Therapeutics announced publication of human genomic and in vivo preclinical data linking iron regulation to polycythemia vera PV in the latest issue of Blood, the medical journal of the American Society of Hematology ASH . The paper is authored by senior medical and scientific experts from Silence and leading population health and hematology researchers from WEHI in Melbourne, Australia as well as Cambride UK. The research, led by WEHI's Dr Cavan Bennett and Professor Sant-Rayn Pasricha, identified links between PV and variants of the iron-regulating gene HFE in a genomewide association study of 440 PV cases and over 400,000 healthy controls. The study further demonstrated in a mouse model of PV that hepcidin, a master regulator of iron availability whose expression is influenced by HFE, governs the red blood cell phenotype in PV. "The phenotype of PV involves the over-production of red blood cells, leading to a range of adverse symptoms and a high risk of life-threatening cardiovascular events," said Dr. Ute Schaeper, Drug Discovery Project Leader at Silence and a co-author on the paper. "The results we reported in Blood provide a genetic and biological rationale for treating PV with SLN124 by raising hepcidin to control systemic iron levels, thus reducing red blood cell count. This therapeutic approach could potentially prevent the need for patients to undergo periodic blood withdrawals to treat their disease and reduce their risk of cardiovascular events without the fluid shifts and severe iron deficiency associated with phlebotomies." SLN124, an siRNA targeting TMPRSS6, is currently being studied in the SANRECO phase 1/2 study in adults with PV. SLN124 is also being studied in other hematological disorders such as beta thalassemia. SLN124 works by silencing TMPRSS6, a gene that negatively regulates hepcidin expression, to increase production of hepcidin in the liver.

07:13 EDT Algernon Pharmaceuticals doses second cohort in Phase 1 DMT study - Algernon Pharmaceuticals advise that its subsidiary Algernon NeuroScience, has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188. AGN Neuro also reports that the safety review committee has approved moving the study forward with the final cohort at an escalated dose after observing no safety or tolerability issues. The trial is being conducted at the Centre for Human Drug Research in Leiden, Netherlands. The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours, a period which has never been studied clinically. In addition, several pharmacodynamic measures believed to be associated with neuroplasticity, including both measurements of biochemical markers and electroencephalographic readings, will be recorded. Once the correct dose has been established in the first part of the study, the second part of the study will include dosing subjects for 6 hours with repeated dosing over a two-week period. There will be up to 60 healthy volunteers enrolled in total, which will include both psychedelic experienced and psychedelic naive subjects. The Company is working with its top stroke and traumatic brain injury experts to design Phase 2 studies for the continued investigation of DMT.

07:12 EDT Sobi announces publication of results from Phase 2 study of emapalumab - Sobi North America announced that the Annals of Rheumatic Diseases has published results from an open-label, single-arm, multicenter phase 2 study evaluating the safety and efficacy of emapalumab, an anti-interferon-gamma monoclonal antibody, being investigated in patients with Systemic Juvenile Idiopathic Arthritis or Adult-onset Still's Disease who developed secondary hemophagocytic lymphohistiocytosis/Macrophage Activation Syndrome following an inadequate response to high-dose glucocorticosteroids. In the published study, 14 patients with sJIA or AOSD and sHLH/MAS who did not respond to high-dose glucocorticosteroids received emapalumab. MAS remission was seen in 13 of the 14 patients by week 8, at a median time of 25 days, based on clinical and laboratory criteria. All 14 patients completed the trial, entered long-term follow-up and were alive at the end of follow-up. Based on the results of this study, Sobi decided to continue to evaluate emapalumab in this patient population and initiated the EMERALD phase 3 study, which is ongoing.

07:10 EDT Autolus Therapeutics announces publication in Molecular Therapy - Autolus Therapeutics announced the publication of a paper in Molecular Therapy titled 'Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.' The company said, "While CD19 CAR T cell therapy has had remarkable success in the treatment of B-cell malignancy, a proportion of patients may relapse with CD19 negative escape." Relapses due to antigen escape are a common cause of treatment failure in pediatric B-ALL. A solution to this is the co-targeting of a 2nd B-lineage antigen. CD22 is expressed early in B-cell development up until plasma cell differentiation and is expressed broadly by B-cell malignancies. Co-targeting of CD19 and CD22 is challenging for two reasons. Firstly, CD22 is a difficult CAR target being bulky and expressed at low density. Secondly, the optimal way of designing a CAR T cell which targets two antigens simultaneously has not been established. In this paper, the Autolus research team first develop a highly sensitive CD22 CAR which can recognize target antigen even if CD22 is expressed at low density. Secondly, they explore a co-transduction approach with the clinically proven Autolus CD19 CAR, Obecabtagene autoleucel. The advantage of a co-transduction approach is that expression of neither obe-cel nor the new CD22 CAR are perturbed. This new CD19/CD22 CAR T cell therapeutic was found to be effective in a mouse model of B-Cell Acute Lymphoblastic Leukemia with CD19 negative escape.

07:08 EDT Tilray's Manitoba Harvest expands whole foods market distribution - Manitoba Harvest, a wholly-owned subsidiary of Tilray Brands, debuts the brand's first Regenerative Organic Certified, ROC, Hemp Hearts exclusively at select Whole Foods Market stores across the United States beginning in April 2023. Following the exclusivity period, the product will continue to be available at Whole Foods Market and other locations throughout the U.S. and Canada. Jared Simon, President at Manitoba Harvest, said, "We are thrilled to expand our distribution with Whole Foods Market with the launch of Manitoba Harvest Regenerative Organic Certified Hemp Hearts as consumer interest in hemp-based foods continues to grow. Over the past year, products with hemp as an ingredient grew 1.5x faster than products with chia and flax, other leading super seeds. As Hemp industry leaders, we're committed to educating consumers about the vast nutritional, sustainable and versatile benefits of hemp by bringing best-in-class products to market."

07:07 EDT Akoustis receives development order from new RF front end module maker customer - Akoustis Technologies announced that it has received a new development order for a Wi-Fi 6E/7 XBAW filter solution for the access point market from a leading Asian RF front-end module maker. Akoustis will help design and develop filters for this new customer, with qualified parts expected in the first half of calendar 2024. Akoustis will help develop two new Wi-Fi 6E and Wi-Fi 7 XBAW filter solutions, leveraging its existing designs, for integration into the front-end modules of this new customer. Headquartered in Asia, this new customer is a leading RF front-end module maker for Wi-Fi applications and plans to enhance its product portfolio through the addition of BAW technology into its Wi-Fi 6E/7 products. Jeff Shealy, founder and CEO of Akoustis stated, "Our XBAW technology continues to be a popular option for 5G mobile and Wi-Fi customers as they can design proprietary filters for their products using our high quality, high-performance technology." Shealy continued, "We expect the number of 5G mobile and Wi-Fi filters that leverage our XBAW technology to expand for the foreseeable future, as well as other filters aimed at many other developing markets."

07:06 EDT Plug Power manufactured 122MW of its 1MW electrolyzer stack platform in Q1 - Plug Power manufactured 122MW of Plug's 1MW electrolyzer stack platform in Q1 2023, an all-time high for the Company and the industry for PEM electrolyzers. Additionally, Plug shipped nearly 1,000 stacks for specialty applications, ranging from a few hundred watts to 150kW, totaling 5.7MW. Plug is on track to ramp its 2.5GW gigafactory in Rochester, NY to 100MW per month in mid-Q2 2023, with plans to further increase output in Q3 2023. "Plug is aggressively pursuing every aspect of the green hydrogen economy, including the expansion of the hydrogen ecosystem and the establishment of top-tier manufacturing and supply chain capabilities," said Plug CEO Andy Marsh. "Plug's large-scale manufacturing capabilities at our state-of-the-art facilities in Rochester and Albany are unrivaled and have helped us to meet the increasing demand for electrolyzers."

07:06 EDT Lannett insulin glargine trial meets endpoints, provides financial update - The pivotal clinical trial of biosimilar insulin glargine demonstrated results, in line with prior expectations. The company is co-developing this product with its strategic alliance partners within the HEC Group of companies. The single center, single-dose, double-blind, randomized, two-period, two-treatment, two-sequence, crossover study was designed to demonstrate pharmacokinetic and pharmacodynamic similarity between Lannett/HECs biosimilar insulin glargine and US-Lantus using the euglycemic clamp technique in healthy male adult volunteers. The study met all of its primary and secondary endpoints and no serious adverse events were reported. The data from the pivotal trial of the Company's biosimilar insulin glargine indicate that its insulin glargine is biosimilar to the reference product. Lannett is moving forward expeditiously to complete the Biologics License Application, with the goal of submitting the application to the FDA within the next several months. Prior to filing, there are additional meaningful activities to complete, including a device differentiation study, which will run in April, and more comparability work showing HEC's insulin glargine is biosimilar to US sourced Lantus. Lannett also anticipates engaging with the FDA in a pre-submission meeting. There are significant steps necessary for the company to receive FDA approval to effectively commercialize this product, and there is no guarantee that the company will be successful in this regard. The company continues to assess the potential impacts of recent developments in the insulin market, including announcements by manufacturers related to lowering the price of insulin for patients, especially list prices, and enhancing market transparency. Lannett welcomes these initiatives to help drive greater access to this critical medicine and believes these changes dovetail with the Company's promising go-to-market approach. As a result of continued competitive pressures on the company's current portfolio and to evaluate options to establish a sustainable capital structure ahead of the launch, subject to approval, of new products, including the company's biosimilar insulin glargine product, the company is in discussions with key secured creditors regarding a potential recapitalization or restructuring of its capital structure. While the company cannot provide any assurance as to if or when it will consummate any such transactions or the terms of any such transactions, the company expects to be able to reach an agreement with its key secured creditors in the near term on such a transaction. Any such potential transaction may involve the restructuring of all or a material portion of the company's outstanding debt, including the exchange of all or a material portion of the secured debt for new common stock or other equity. Holders of the company's common stock and convertible notes may not receive any value or payments in a recapitalization, restructuring or similar transaction and/or may experience material dilution or the loss or cancellation of their investment. The terms of any transaction will depend on prevailing market conditions, the company's liquidity requirements and cash position, contractual restrictions, trading prices of debt from time to time and other factors. As such, the company elected to defer an interest payment on certain of the company's unsecured convertible notes and enter a 30-day grace period. The Company's election to not make the interest payment was not driven by liquidity constraints as the Company has approximately $47M of unrestricted cash as of March 31. If the company does not make this interest payment within the 30-day grace period, it will constitute an event of default under the indenture governing the convertible notes. If an event of default occurs, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding convertible notes may declare 100% of the principal of, and accrued and unpaid interest on, all the convertible notes to be due and payable immediately.

07:05 EDT Steakholder Foods announces closure of Belgian subsidiary - Steakholder Foods announced the closure of its wholly owned subsidiary, Peace of Meat BV, as a means to optimize its funds and investment strategy, alongside enabling a greater focus on recently-announced core goals such as accelerating the commercialization of its 3D printing technology. As part of the company's purchase of the shares of PoM at the end of 2020, PoM's management had been granted full contractual autonomy throughout 2021 and 2022, and was provided with the funding required to develop its technologies in accordance with the terms of the purchase. Following the conclusion of the autonomous period and following its previously announced plans to restructure PoM, the company further evaluated the expected return on its investment, and decided not to further fund PoM, in order to focus its efforts in the advancement of its core technology 3D printing of cultured products, and potential collaborations. As a result, PoM has ceased operations and is expected to be liquidated. As part of this process, Steakholder Foods expects PoM's assets to be realized, following which the company shall consider how and when to continue development of cultivated avian products. The closure of PoM is expected to reduce Steakholder Foods' expenses by about $4.5M annually, relative to 2022.

07:04 EDT Ginkgo Bioworks, Solvay announce strategic collaboration - Solvay announced a strategic collaboration with Ginkgo Bioworks. Through this multi-year strategic collaboration agreement, Solvay will join forces with Ginkgo to unlock the power of synthetic biology as an enabler of more sustainable chemicals and materials, contributing to the transition towards more environmentally-friendly solutions. This alliance will start by focusing on new sustainable biopolymers, specialties which could tangibly impact a breadth of markets, from home and personal care to agriculture and food. As part of this partnership, Solvay will also acquire a Ginkgo laboratory in Cambridge, Massachusetts. This acquisition will expand Solvay's research and innovation footprint in the US, provide Solvay access to new talents, and establish a sustainable growth base in synthetic biology in one the most important biotech hubs in the world, accelerating the company's biotech development plan. With this strategic collaboration and expansion, Solvay will integrate deep competencies in bioinformatics and data science, strain engineering, biocatalysis and fermentation processes, strengthening and accelerating the ability to scout, develop and turn into businesses the most valuable biotech-enabled opportunities.

06:57 EDT Golden Minerals announces improved terms for Velardena Properties concentrates - Golden Minerals announced that it is selling gold-rich pyrite concentrates from its Velardena Properties on improved terms to a buyer in Manzanillo, Mexico. Warren Rehn, Golden's President and CEO, commented, "Recently improved and updated terms for the purchase of our gold-rich pyrite concentrates allow us to consider moving forward with the re-opening of the Velardena Properties' mines without the need to build the BIOX plant, as we had previously planned. The new terms pay for enough of the gold and silver in the concentrate to enable us to shelve plans for the BIOX plant and sell our flotation concentrates directly to smelters. We made our first shipment of 142 tonnes of previously produced and stockpiled gold-rich pyrite concentrate under the new terms last week and we are currently processing 3,000 tonnes of previously mined and stockpiled mineralized material from the Santa Juana mine for future shipments. The economic benefit of the new payable terms bodes well for a restart of the Velardena mines." The new payable terms for gold-bearing pyrite concentrates are a significant improvement over previous terms offered in 2022 and earlier, and now represent in excess of a 100% increase for gold payables in the concentrate. The Company had previously planned to construct a BIOX facility at Velardena in order to recover the gold in the pyrite concentrate. The capital cost of the BIOX facility was initially estimated at approximately US $6.5 million in 2019 (as reported in the May 2020 PEA); however, upon re-estimation in 2021 (as reported in the March 2022 PEA) the cost estimate had more than doubled to $14.5 million. In 2022, detailed costing and design showed a minimum cost of well over $20 million, which was more than could be readily financed for the project. The increase in the BIOX plant costs created uncertainty about the economic feasibility of re-commencing production. With these new concentrate sales terms, the problem of payable gold recovery appears to be solved without the significant capital costs required to build the previously planned BIOX facility. The company is now evaluating the economics of a restart of the Velardena operation without the need for major capital expenditures for the BIOX facility and ancillary equipment. Pending confirmation and Board approval of the start-up plan, the company believes that it could commence production as soon as mid-2023. To address the concerns related to mining dilution at Velardena, the company anticipates that it would schedule initial production from those veins that showed the best results from test mining in 2022. Ore-sorting, while showing promise to help reduce dilution, would not be required for the currently envisioned plan to resume production given the improved revenue projected from the new concentrate sales terms.

06:51 EDT ANI Pharmaceuticals announces FDA approval of Colestipol Hydrochloride Tablets - ANI Pharmaceuticals announced that it received U.S. FDA approval for the Abbreviated New Drug Application for Colestipol Hydrochloride Tablets USP, 1 g. ANI's Colestipol Hydrochloride Tablets are the generic version of the Reference Listed Drug Colestid. The current annual U.S. market for Colestipol Hydrochloride Tablets is approximately $81.3M, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.

06:48 EDT Pfizer: FDA accepts sNDAs for BRAFTOVI + MEKTOVI - Pfizer announced that the U.S. FDA has accepted for review the Supplemental New Drug Applications for BRAFTOVI + MEKTOVI for patients with metastatic non-small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test. The Prescription Drug User Fee Act goal date for a decision by the FDA is in Fourth-Quarter 2023 for the sNDAs. In the U.S., BRAFTOVI + MEKTOVI is currently approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. BRAFTOVI is also approved, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

06:37 EDT MSC Industrial backs FY23 adjusted operating margin view 12.7%-13.3% - Backs FY23 average daily sales growth view 5%-9%.

06:33 EDT Thomson Reuters launches return of $2.2B to stockholders - Thomson Reuters (TRI) finalized its planned uses of its approximate $2.3B of gross proceeds related to dispositions of shares in London Stock Exchange Group co-owned by the company and certain investment funds affiliated with Blackstone (BX) completed thus far in 2023. As previously disclosed in February , the company plans to use the gross proceeds related to the LSEG transactions to provide returns to shareholders. In connection therewith, approximately $2.2B will be returned to shareholders through a return of capital transaction consisting of a cash distribution of $4.67 per common share and a share consolidation, or "reverse stock split", which will reduce the number of outstanding common shares on a basis that is proportional to the cash distribution.

06:03 EDT Vivani Medical awarded $1M NIH grant for Orion prosthesis study - Vivani Medical received notice from the National Institutes of Health - NIH - of approval of the year 5 funding for the Early Feasibility Clinical Study of the Orion Visual Cortical Prosthesis being conducted by its newly formed subsidiary, Cortigent. This represents the final $1M funding of the original $6.4M five-year grant award. Cortigent was formed by Vivani Medical to continue the work of its Neuromodulation Division, formerly Second Sight Medical Products. Cortigent will use these funds to support the Orion clinical trial currently underway at UCLA. The Orion Visual Cortical Prosthesis is being developed with the goal of providing meaningful artificial vision to profoundly blind people. The 5-year results for the Orion Early Feasibility Study are expected in mid-2023.

05:36 EDT Metalpha Technology receives noncompliance notice from Nasdaq - Metalpha Technology announced that it received a written notice from Nasdaq which states the company has regained compliance with the minimum bid price requirement set forth under the Nasdaq Listing Rule 5550 and currently meets all other applicable criteria for continued listing. As previously announced, the company received a written notification on September 21 from Nasdaq that the company was not in compliance with the minimum bid price requirement as the closing bid price of the company's ordinary shares was below $1.00 per share for a period of 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810, the company was provided 180 calendar days, or until March 20, to regain compliance with the minimum bid price requirement. To regain compliance, the company's ordinary shares must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

05:24 EDT Addex Therapeutics announces dipraglurant data for Parkinson's patients - Addex Therapeutics announced data showing that dipraglurant could have beneficial effects on non-motor symptoms, or NMS, experienced by Parkinson's patients in addition to its established positive effects on dyskinesias. Dipraglurant is an mGlu5 negative allosteric modulator, or NAM, that has successfully completed a Phase 2a study in Parkinson's disease patients suffering from levodopa induced dyskinesia, or PD-LID. In the current study, published in Cells, the effects of dipraglurant were investigated in a rodent motor symptoms model of PD, as well as anxiety, depression and obsessive-compulsive disorder, all of which are among the most prevalent NMS symptoms. Following oral administration, dipraglurant was rapidly absorbed and readily crossed the blood-brain barrier. In vivo, dipraglurant administration was found to dose-dependently impact the various NMS disease models, including reducing haloperidol-induced catalepsy, increasing punished licks in the Vogel conflict-drinking model, decreasing immobility time in the forced swim test and decreasing the number of buried marbles in the marble-burying test. Dipraglurant was found to have no effect on rotarod performance or locomotor activity.

05:19 EDT OKYO Pharma to delist from London Stock Exchange - OKYO Pharma announced that it has applied to the UK Financial Conduct Authority, or FCA, and London Stock Exchange to effect a cancellation of its ordinary shares of no par value each from listing on the standard segment of the FCA's Official List and trading on the main market for listed securities of the LSE.

05:14 EDT Magnite opens new office in Stockholm - Magnite announced the appointment of Natasha Westlund as the Head of Nordics and the opening of a new office in Stockholm, which will serve as the company's base across Sweden, Denmark, Norway, and Finland. As Head of Nordics, Natasha is the commercial lead across both seller and buyer teams building the company's business in the region. Natasha is based in the company's Stockholm office and reports to Magnite's SVP Head of EMEA Julie Selman.

05:10 EDT ChargePoint enters international agreement with ALD Automotive - ALD Automotive has signed an international agreement with ChargePoint, an electric vehicle, or EV, charging network, to create a new EV charging business in Europe for international and local corporate clients. The joint initiative aims to create a unique electric Mobility Service Provider, or eMSP, to accelerate corporate fleet electrification. The new charging business will provide drivers of corporate fleets with one charging solution, payments and reimbursement reports. Drivers will access a charging network of over 485,000 charging ports across Europe, with a single dedicated app and charging card offering charging at home, in the office or on the road.